Search research articles
Contact Us
Filters
Showing results (1-10 of 105) with videos related to
Page
of 11
Sort By:
JAMA Network Open
|
October 16, 2024
Value and Affordability of Shelter-Based Opioid Treatment Among People Experiencing Homelessness
Mark Bounthavong
Journal of the American Pharmacists Association : Japha
|
March 9, 2026
Is there a principal-agent problem between large retail-chain pharmacy corporations and community pharmacists?
Mark Bounthavong
Journal of the American Pharmacists Association : Japha
|
February 15, 2024
Despair and hope: Is the retail community pharmacy workforce in danger of becoming a monopsony labor market?
Mark Bounthavong
JAMA Network Open
|
April 14, 2023
Is Providing Medications for Opioid Use Disorder to Incarcerated Individuals a Cost-effective Strategy?
Mark Bounthavong
Journal of Managed Care & Specialty Pharmacy
|
November 24, 2021
Cancer history, insurance coverage, and cost-related medication nonadherence in Medicare beneficiaries, 2013-2018
Meng Li, Mark Bounthavong
Journal of General Internal Medicine
|
July 26, 2019
Medicare Beneficiaries, Especially Unsubsidized Minorities, Struggle to Pay for Prescription Drugs: Results from the Medicare Current Beneficiary Survey
Meng Li, Mark Bounthavong
Clinicoeconomics and Outcomes Research : CEOR
|
September 22, 2011
Cost-effectiveness analysis of intravenous levetiracetam versus intravenous phenytoin for early onset seizure prophylaxis after neurosurgery and traumatic brain injury
Rashid Kazerooni, Mark Bounthavong
Pharmacotherapy
|
June 8, 2012
Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel: a commentary
Nermeen Madkour, Mark Bounthavong
Applied Health Economics and Health Policy
|
July 20, 2025
Enhancing Naloxone Distribution for Opioid Users in the USA: A Cost-Utility Analysis of Academic Detailing to Clinicians
Olivia Yip, Mark Bounthavong
Pharmacoeconomics
|
June 3, 2026
Cost-Utility Analysis of Calcitonin Gene-Related Peptide Monoclonal Antibodies for Patients with Episodic Migraine Headache in the USA
Ariel Weiming Dong, Mark Bounthavong
Page
of 11
Search research articles
Search
Showing results (1-10 of 105) with videos related to
Sort By:
Page
of 11
JAMA Network Open
|
October 16, 2024
Value and Affordability of Shelter-Based Opioid Treatment Among People Experiencing Homelessness
Mark Bounthavong
Journal of the American Pharmacists Association : Japha
|
March 9, 2026
Is there a principal-agent problem between large retail-chain pharmacy corporations and community pharmacists?
Mark Bounthavong
Journal of the American Pharmacists Association : Japha
|
February 15, 2024
Despair and hope: Is the retail community pharmacy workforce in danger of becoming a monopsony labor market?
Mark Bounthavong
JAMA Network Open
|
April 14, 2023
Is Providing Medications for Opioid Use Disorder to Incarcerated Individuals a Cost-effective Strategy?
Mark Bounthavong
Journal of Managed Care & Specialty Pharmacy
|
November 24, 2021
Cancer history, insurance coverage, and cost-related medication nonadherence in Medicare beneficiaries, 2013-2018
Meng Li, Mark Bounthavong
Journal of General Internal Medicine
|
July 26, 2019
Medicare Beneficiaries, Especially Unsubsidized Minorities, Struggle to Pay for Prescription Drugs: Results from the Medicare Current Beneficiary Survey
Meng Li, Mark Bounthavong
Clinicoeconomics and Outcomes Research : CEOR
|
September 22, 2011
Cost-effectiveness analysis of intravenous levetiracetam versus intravenous phenytoin for early onset seizure prophylaxis after neurosurgery and traumatic brain injury
Rashid Kazerooni, Mark Bounthavong
Pharmacotherapy
|
June 8, 2012
Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel: a commentary
Nermeen Madkour, Mark Bounthavong
Applied Health Economics and Health Policy
|
July 20, 2025
Enhancing Naloxone Distribution for Opioid Users in the USA: A Cost-Utility Analysis of Academic Detailing to Clinicians
Olivia Yip, Mark Bounthavong
Pharmacoeconomics
|
June 3, 2026
Cost-Utility Analysis of Calcitonin Gene-Related Peptide Monoclonal Antibodies for Patients with Episodic Migraine Headache in the USA
Ariel Weiming Dong, Mark Bounthavong
Page
of 11